Abbott Laboratories (ABT) Stake Boosted by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 48.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 362,167 shares of the healthcare product maker’s stock after purchasing an additional 118,285 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Abbott Laboratories were worth $26,568,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ABT. BlackRock Inc. raised its holdings in shares of Abbott Laboratories by 3.7% during the second quarter. BlackRock Inc. now owns 116,149,740 shares of the healthcare product maker’s stock worth $7,083,972,000 after acquiring an additional 4,153,157 shares during the period. Morgan Stanley increased its stake in Abbott Laboratories by 33.1% in the 2nd quarter. Morgan Stanley now owns 21,218,276 shares of the healthcare product maker’s stock valued at $1,294,103,000 after buying an additional 5,274,307 shares during the last quarter. Janus Henderson Group PLC increased its stake in Abbott Laboratories by 12.0% in the 2nd quarter. Janus Henderson Group PLC now owns 13,708,172 shares of the healthcare product maker’s stock valued at $836,067,000 after buying an additional 1,468,430 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Abbott Laboratories by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 9,477,591 shares of the healthcare product maker’s stock valued at $578,069,000 after buying an additional 67,093 shares during the last quarter. Finally, Swiss National Bank increased its stake in Abbott Laboratories by 3.3% in the 2nd quarter. Swiss National Bank now owns 5,998,788 shares of the healthcare product maker’s stock valued at $365,866,000 after buying an additional 190,600 shares during the last quarter. 72.30% of the stock is currently owned by institutional investors.

Several equities research analysts have issued reports on ABT shares. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research note on Tuesday, September 18th. Barclays started coverage on shares of Abbott Laboratories in a research note on Monday, October 15th. They issued an “overweight” rating and a $80.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of Abbott Laboratories from $77.00 to $81.00 and gave the company an “overweight” rating in a research note on Monday, October 8th. Wells Fargo & Co lifted their price target on shares of Abbott Laboratories from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, September 24th. Finally, Cowen lifted their price target on shares of Abbott Laboratories from $72.00 to $86.00 and gave the company an “average” rating in a research note on Friday, October 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $75.22.



Abbott Laboratories stock opened at $67.31 on Tuesday. The stock has a market cap of $117.52 billion, a PE ratio of 26.92, a PEG ratio of 1.99 and a beta of 1.49. Abbott Laboratories has a fifty-two week low of $53.61 and a fifty-two week high of $74.15. The company has a current ratio of 1.58, a quick ratio of 1.16 and a debt-to-equity ratio of 0.64.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 17th. The healthcare product maker reported $0.75 earnings per share for the quarter, hitting the consensus estimate of $0.75. The company had revenue of $7.66 billion for the quarter, compared to analyst estimates of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.01%. Abbott Laboratories’s revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 EPS. Research analysts expect that Abbott Laboratories will post 2.89 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 15th. Stockholders of record on Monday, October 15th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, October 12th. This represents a $1.12 annualized dividend and a dividend yield of 1.66%. Abbott Laboratories’s dividend payout ratio is presently 44.80%.

In related news, SVP Sharon J. Bracken sold 1,732 shares of Abbott Laboratories stock in a transaction dated Friday, September 28th. The shares were sold at an average price of $73.35, for a total transaction of $127,042.20. Following the completion of the sale, the senior vice president now owns 39,229 shares of the company’s stock, valued at approximately $2,877,447.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jaime Contreras sold 64,268 shares of Abbott Laboratories stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $66.84, for a total transaction of $4,295,673.12. Following the sale, the senior vice president now directly owns 125,471 shares of the company’s stock, valued at approximately $8,386,481.64. The disclosure for this sale can be found here. Insiders have sold a total of 138,297 shares of company stock worth $9,403,743 over the last 90 days. 0.74% of the stock is owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply